 Connection
David Fox to Anti-Citrullinated Protein Antibodies
This is a "connection" page, showing publications David Fox has written about Anti-Citrullinated Protein Antibodies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.349 |
|
|
|
-
Deane KD, Striebich CC, Feser ML, O'Dell JR, James JA, Sparks JA, Davis JM, Graf J, McMahon MA, Solow EB, Forbess LJ, Tiliakos A, Schiopu E, Danila MI, Horowitz DL, Kay J, Strickland CD, Guthridge JM, Arriens C, Grossman JM, Kristen Demoruelle M, Bemis EA, Frazer-Abel A, Fleischer CL, Fox DA, Mikuls TR, Greenleaf M, York K, Walker S, Keyes-Elstein L, Byron M, Fedler J, Goldmuntz EA, Holers VM. A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2026 Apr; 78(4):809-820.
Score: 0.214
-
Ohara RA, Edhayan G, Rasmussen SM, Isozaki T, Remmer HA, Lanigan TM, Campbell PL, Urquhart AG, Lawton JN, Chung KC, Fox DA, Ruth JH. Citrullinated Inhibitor of DNA Binding 1 Is a Novel Autoantigen in Rheumatoid Arthritis. Arthritis Rheumatol. 2019 08; 71(8):1241-1251.
Score: 0.134
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|